{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:39Z","timestamp":1790096919593,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/04378\/2025"],"award-info":[{"award-number":["UID\/04378\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104765","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:25:29Z","timestamp":1786465529000},"page":"104765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current Clinical Evidence on Nose-to-Brain Drug Delivery"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6923-0232","authenticated-orcid":false,"given":"A.C.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104765_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104765_b0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.drudis.2026.104765_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124866","article-title":"Advancement in the nose-to-brain drug delivery of FDA-approved drugs for the better management of depression and psychiatric disorders","volume":"667","author":"Upadhyay","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-brain delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104765_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-025-00481-w","article-title":"Nose-to-brain drug delivery: from bench to bedside","volume":"14","author":"Drath","year":"2025","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.drudis.2026.104765_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114485","article-title":"Lipid nanoparticle strategies to modify pharmacokinetics of central nervous system-targeting drugs: crossing or circumventing the blood\u2013brain barrier to manage neurological disorders","volume":"189","author":"Correia","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2026.104765_b0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104765_b0040","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.2147\/IJN.S305851","article-title":"Improving drug delivery for Alzheimer's disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers and in situ hydrogels","volume":"16","author":"Cunha","year":"2021","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2026.104765_b0045","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/pharmaceutics16101297","article-title":"Enhancing acute migraine treatment: exploring solid lipid nanoparticles and nanostructured lipid carriers for the nose-to-brain route","volume":"16","author":"Torres","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104765_b0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier-mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2026.104765_b0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0060","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A decade of FDA-approved drugs (2010\u20132019): trends and future directions","volume":"64","author":"Brown","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104765_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117241","article-title":"New FDA drug approvals for 2024: synthesis and clinical application","volume":"285","author":"Wang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104765_b0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017018693","article-title":"Lipid nanoparticles for nasal\/intranasal drug delivery","volume":"34","author":"Cunha","year":"2017","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.drudis.2026.104765_b0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mattod.2020.02.001","article-title":"Overcoming blood\u2013brain barrier transport: advances in nanoparticle-based drug delivery strategies","volume":"37","author":"Ding","year":"2020","journal-title":"Mater Today"},{"key":"10.1016\/j.drudis.2026.104765_b0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10787-024-01636-3","article-title":"Advancements in nose-to-brain drug targeting for Alzheimer's disease: a review of nanocarriers and clinical insights","volume":"33","author":"Komal","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.drudis.2026.104765_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124631","article-title":"Design of experiment (DoE) of mucoadhesive valproic acid-loaded nanostructured lipid carriers for potential nose-to-brain application","volume":"664","author":"Correia","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0090","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1080\/17425247.2023.2274902","article-title":"Design of experiment (DoE) as a quality by design (QbD) tool to optimise formulations of lipid nanoparticles for nose-to-brain drug delivery","volume":"20","author":"Correia","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.drudis.2026.104765_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120933","article-title":"Quality by design (QbD) optimisation of diazepam-loaded nanostructured lipid carriers for nose-to-brain delivery: toxicological effect of surface charge on human neuronal cells","volume":"607","author":"Costa","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/pharmaceutics12070599","article-title":"Double optimisation of rivastigmine-loaded nanostructured lipid carriers for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters","volume":"12","author":"Cunha","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104765_b0105","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1956","article-title":"Nose-to-brain delivery of nanotherapeutics: transport mechanisms and applications","volume":"16","author":"Xu","year":"2024","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"10.1016\/j.drudis.2026.104765_b0110","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.apsb.2022.07.003","article-title":"Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders","volume":"13","author":"Awad","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104765_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123345","article-title":"In situ hydrogel containing diazepam-loaded nanostructured lipid carriers for nose-to-brain delivery: development, characterization and deposition studies in a 3D-printed human nasal cavity model","volume":"644","author":"Pina Costa","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126166","article-title":"Maximising olfactory deposition of a valproic acid-loaded nanostructured lipid carrier formulation","volume":"684","author":"Correia","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121720","article-title":"Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterization, biocompatibility and drug deposition studies","volume":"620","author":"Cunha","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/ph14080711","article-title":"In vitro studies on nasal formulations of nanostructured lipid carriers and solid lipid nanoparticles","volume":"14","author":"Costa","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2026.104765_b0135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.addr.2020.09.002","article-title":"In vitro\u2013in vivo correlation of intranasal drug deposition","volume":"170","author":"Le Guellec","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2026.104765_b0140","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/pharmaceutics13071079","article-title":"In vitro evaluation of nasal aerosol deposition: an insight into direct nose-to-brain drug delivery","volume":"13","author":"Maaz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104765_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2022.924501","article-title":"Instillation of a dry powder in nasal casts: parameters influencing olfactory deposition with uni- and bi-directional devices","volume":"4","author":"Rigaut","year":"2022","journal-title":"Front Med Technol"},{"key":"10.1016\/j.drudis.2026.104765_b0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","article-title":"How to characterize a nasal product: the state of the art of in vitro and ex vivo specific methods","volume":"561","author":"Salade","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/pharmaceutics14071353","article-title":"In vitro anatomical models for nasal drug delivery","volume":"14","author":"Williams","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104765_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123922","article-title":"An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting","volume":"654","author":"Wong","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0165","article-title":"The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters","volume":"21","author":"Chung","year":"2023","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.drudis.2026.104765_b0170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/pharmaceutics16010066","article-title":"Nose-to-brain (N2B) delivery: an alternative route for the delivery of biologics in the management and treatment of central nervous system disorders","volume":"16","author":"Patharapankal","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104765_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125584","article-title":"The review of nasal drug delivery systems: strategies to enhance the efficiency of intranasal drug delivery by improving drug absorption","volume":"676","author":"Wei","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0180","doi-asserted-by":"crossref","first-page":"12343","DOI":"10.2147\/IJN.S497480","article-title":"Nose to brain: exploring the progress of intranasal delivery of solid lipid nanoparticles and nanostructured lipid carriers","volume":"19","author":"Zheng","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2026.104765_b0185","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies","volume":"11","author":"Costa","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104765_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibtech.2025.12.011","article-title":"The FDA's plan to phase out animal testing","author":"Gerke","year":"2026","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.drudis.2026.104765_b0195","doi-asserted-by":"crossref","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/j.drudis.2026.104765_b0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104765_b0205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","article-title":"Drug delivery to the brain via the nasal route of administration: exploration of key targets and major considerations","volume":"53","author":"Jeong","year":"2023","journal-title":"J Pharm Investig"},{"key":"10.1016\/j.drudis.2026.104765_b0210","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.2147\/IJN.S520768","article-title":"Brain delivery strategies for biomacromolecular drugs: intranasal administration","volume":"20","author":"Wu","year":"2025","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2026.104765_b0215","article-title":"Intranasal drug delivery: unlocking the nose-to-brain route for central nervous system therapies","volume":"11","author":"Alwali","year":"2026","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.drudis.2026.104765_b0220","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1208\/s12249-024-02810-0","article-title":"In-depth mechanism, challenges and opportunities of delivering therapeutics to the brain using the intranasal route","volume":"25","author":"Ghosh","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.drudis.2026.104765_b0225","series-title":"European Pharmacopoeia","author":"European Directorate for the Quality of Medicines & HealthCare (EDQM)","year":"2021"},{"key":"10.1016\/j.drudis.2026.104765_b0230","unstructured":"European Medicines Agency. Guideline on the pharmaceutical quality of inhalation and nasal medicinal products. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-pharmaceutical-quality-inhalation-nasal-medicinal-products_en.pdf (accessed 10 April 2025)."},{"key":"10.1016\/j.drudis.2026.104765_b0235","unstructured":"European Medicines Agency. ICH guideline Q8(R2) on pharmaceutical development. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-considerations-ich-guideline-q8-r2-pharmaceutical-development-step-5_en.pdf (accessed 10 April 2025)."},{"key":"10.1016\/j.drudis.2026.104765_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124851","article-title":"Characterization of anatomical variations of the nasal cavity in a subset of European patients and their impact on intranasal drug delivery","volume":"667","author":"Pasteur","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104765_b0245","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.17227","article-title":"Comparative study of nasal cavity drug delivery efficiency with different nozzles in a 3D-printed model","volume":"12","author":"Fang","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.drudis.2026.104765_b0250","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3390\/pharmaceutics15122661","article-title":"What are the key anatomical features for the success of nose-to-brain delivery? A study of powder deposition in 3D-printed nasal casts","volume":"15","author":"Rigaut","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104765_b0255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcpa.2015.08.009","article-title":"A review of the comparative anatomy, histology, physiology and pathology of the nasal cavity of rats, mice, dogs and non-human primates: relevance to inhalation toxicology and human health risk assessment","volume":"153","author":"Chamanza","year":"2015","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.drudis.2026.104765_b0260","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.70086","article-title":"Pharmacokinetics and bioavailability of a novel rivastigmine nasal spray compared with rivastigmine oral capsules in healthy men","volume":"66","author":"Morgan","year":"2026","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104765_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00581","article-title":"Intranasal insulin for improving cognitive function in multiple sclerosis","volume":"22","author":"Newsome","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2026.104765_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2025.101509","article-title":"Intranasal insulin for the treatment of alcohol use disorder: design and methodology of an alcohol interaction randomised controlled trial","volume":"46","author":"Haass-Koffler","year":"2025","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.drudis.2026.104765_b0275","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15665","article-title":"A single-dose, randomized, open-label, parallel-design study to characterize the pharmacokinetics of an investigational olanzapine intranasal spray compared to a reference dose of olanzapine intramuscular injection in healthy adult males","volume":"86","author":"Madden","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.drudis.2026.104765_b0280","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-091125","article-title":"AEROfen: protocol for a phase I, open-label, randomized crossover study evaluating the efficiency of nebulised fentanyl in healthy volunteers comparing facial versus intranasal administration via pharmacometric modelling","volume":"15","author":"Follet","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2026.104765_b0285","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1210\/clinem\/dgae479","article-title":"Effects of intranasal naloxone on hypoglycemia-associated autonomic failure in susceptible individuals","volume":"110","author":"Aleksic","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.drudis.2026.104765_b0290","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ipd.13261","article-title":"Sedative and behavioral effects of atomized intranasal midazolam compared to nebulised midazolam in children undergoing dental treatment: a randomized clinical trial","volume":"35","author":"Elkhatib","year":"2025","journal-title":"Int J Paediatr Dent"},{"key":"10.1016\/j.drudis.2026.104765_b0295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.17245\/jdapm.2025.25.2.109","article-title":"Comparative evaluation of the effectiveness and acceptance of intranasal dexmedetomidine and intranasal midazolam for sedation in children aged 5\u20138 years using a mucosal atomizer device: a randomized controlled clinical study","volume":"25","author":"Lalwani","year":"2025","journal-title":"J Dent Anesth Pain Med"},{"key":"10.1016\/j.drudis.2026.104765_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105689","article-title":"Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans","volume":"115","author":"Mills","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2026.104765_b0305","doi-asserted-by":"crossref","DOI":"10.3171\/CASE24683","article-title":"Patient with recurrent grade 4 astrocytoma responding favorably to intranasal delivery of NEO100, highly pure perillyl alcohol: illustrative case","volume":"9","author":"Sch\u00f6nthal","year":"2025","journal-title":"J Neurosurg Case Lessons"},{"key":"10.1016\/j.drudis.2026.104765_b0310","article-title":"First-in-class intranasal epinephrine spray for anaphylaxis: dose-finding clinical study","volume":"4","author":"Lapidot","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.drudis.2026.104765_b0315","unstructured":"ClinicalTrials.gov. Intranasal administration: clinical trials with results. Available at: https:\/\/clinicaltrials.gov\/search?cond=Intranasal%20administration&aggFilters=results:with,status:com,studyType:int&viewType=Card (accessed 5 March 2026)."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:18:48Z","timestamp":1790093928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001704"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104765","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Clinical Evidence on Nose-to-Brain Drug Delivery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104765"}}